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HELMUT SCHU¨HLEN, MD, FACC
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Background. The long-term results after coronary stent
placement are limited by in-stent restenosis. There is
growing evidence that the characteristics of coronary stents
may have a significant impact on the development of
restenosis. In the ISAR-STEREO-1 trial, previously pub-
lished in Circulation, we have found that the use of stents
with thinner struts is associated with a significant reduction
in restenosis. This was observed in a randomized compari-
son of two stents with very similar design but different strut
thickness (Guidant ACS RX MultiLink stent [strut thick-
ness, 50 m] vs. MultiLink RX Duet [strut thickness,
140 m]). The purpose of ISAR-STEREO-2 was to assess
whether the impact of strut thickness is also evident with
stents of different design. Methods. In this multicenter trial,
611 patients with lesions in native coronary arteries
2.8 mm in diameter were randomly assigned to either the
“thin-strut” Guidant ACS RX MultiLink stent (strut thick-
ness, 50 m; n  309) or the “thick-strut” Cordis BX
Velocity stent (strut thickness, 140 m; n  302). These
two stents also differ with respect to strut configuration and
design. The primary end point was angiographic restenosis
at follow-up angiography. Secondary end points were
target-vessel revascularization (TVR) and the combined rate
of death and myocardial infarction (MI) at one year.
Results. At baseline, there were no relevant differences in
clinical or angiographic baseline characteristics between the
two groups. Procedural success rates were similar in both
groups (99.4% vs. 99.0%), whereas device success (i.e.,
procedural success with the randomly assigned device) was
significantly lower with thin-strut stents (87.1% vs. 99.0%;
p  0.001). Short-term quantitative angiographic results
were almost identical in the two groups. At six-month
angiography, however, late luminal loss was significantly
lower in the thin-strut group (0.93 mm vs. 1.19 mm; p 
0.001), as was the loss index (0.51 vs. 0.65; p 0.001). This
translated into a significant difference in the primary end
point, the angiographic restenosis rate (17.9% vs. 31.4%;
p  0.001). At one year, the rate of TVR was significantly
lower with thin-strut stents (12.3% vs. 21.9%; p  0.002);
no difference was observed in the combined rate of death
and MI at one year (4.9% vs. 6.3%; p 0.67). Conclusions.
Strut thickness of coronary stents has a significant impact on
long-term outcome because thinner-strut stents are associ-
ated with a significantly lower restenosis rate. The ISAR-
STEREO-1 trial had shown this effect in a comparison of
two stents of similar design; ISAR-STEREO-2 suggests
that this effect is also true for stents of different design. The
findings could have an important impact on today’s practice
and the future development of coronary stents. The trial
underscores the value of an unselected study population and
a stringent follow-up of at least six months, as well as the
limited value of data on short-term procedural success and
early results.
COMMENTARY
This multicenter trial has significant implications for the
practice of interventional cardiology. We have grown up
with the concept of “equivalence” trials as companies and
investigators have evaluated new generations of stents. In
the majority of stent-to-stent comparison trials from the late
1990s, different stents were found to be equivalent or at least
non-inferior to the initially approved Johnson & Johnson
Palmaz-Schatz coronary stent. The ISAR investigators
previously found, in ISAR-STEREO-1, that not all stents
are equal.
This study, ISAR-STEREO-2, builds on that question
of equivalence and compares the performance of two dif-
ferent stents—one arguably among the most widely used in
the world and the other no longer even available, at least in
the U.S. Differences in stent design included stent config-
uration and thickness. The findings were very interesting—
device success was less satisfactory with the thin-strut stents,
but procedural success was the same and for both, at 99%.
The most important finding was that, although short-term
quantitative coronary angiographic results were almost iden-
tical, the late loss index was significantly lower with the
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thin-strut stent, resulting in significantly lower restenosis
rates at 17.9% versus 31.4%, respectively; and with the thin-
strut stent, accordingly, the rate of TVR was also lower.
Several unanswered questions remain, such as what is the
optimal deployment pressure and the appropriate balloon
size at that pressure. Answers to these will be forthcoming.
The important message is that form and substance continue
to matter and must be taken into consideration for future
stent design and study development. To paraphrase George
Orwell: All stents are equal—some are more equal than
others.
DAVID R. HOLMES, JR, MD, FACC
Acute Myocardial Infarction Study of Adenosine
(AMISTAD II)
ALLAN M. ROSS, MD, FACC
GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER,
WASHINGTON, DC
Background. A previous study (AMISTAD I) of adenosine
given with fibrinolytic therapy to patients with acute myo-
cardial infarction (MI) suggested that it reduced infarct size.
Characteristics of adenosine that may contribute to this
benefit include involvement in high-energy phosphate me-
tabolism, an antiplatelet effect, and suppression of free-
radical formation and neutrophil activation. Methods. To
further evaluate the possible benefits of adenosine for
myocardial protection in acute MI, a randomized, double-
blind, placebo-controlled trial was performed with 2,118
patients at 248 clinical sites in 13 countries. A 263-patient
substudy was performed at 62 sites in four countries, using
technetium-99m sestamibi single photon emission com-
puted tomography (SPECT) 120 to 216 h after random-
ization for assessment of final infarct size. Eligible patients
with evolving anterolateral MI were randomized to receive
a 3-h infusion of adenosine at 50g/kg/min, at 70g/kg/min,
or placebo within 15 min of the start of fibrinolytic therapy
or within 15 min prior to infarct-artery angioplasty. Patients
were followed up until hospital discharge and for the next
six months. The primary efficacy end point was time from
randomization to the first occurrence of congestive heart
failure (CHF) in-hospital but 24 h after randomization,
the first rehospitalization for CHF during follow-up, or
death from any cause. The secondary efficacy end points
were all-cause mortality, cardiovascular mortality, and in-
farct size as measured by SPECT imaging. Results. Aden-
osine was well tolerated at both dosages and in comparison
with placebo. On an intention-to-treat basis, the risk for the
primary clinical end point was reduced by 11% over six
months for patients in the two adenosine dosage groups
combined. The reduction did not reach statistical signifi-
cance. However, the corresponding risk reduction did reach
significance (p  0.043) for the subgroup that achieved
successful reperfusion and received adenosine. Infarct size
by SPECT was not significantly different in the pooled
adenosine group and the control group. Among the group
that received adenosine at the higher dosage, however,
SPECT infarct size was significantly reduced by 27% (p 
0.028). The median infarct size was 43% among patients
experiencing death, heart failure, or both and 17% among
patients without such events. Infarct size and such clinical
events were significantly correlated (p  0.01) by the
Spearman rank test. Conclusions. We conclude that among
patients who underwent reperfusion therapy: 1) there was a
trend toward reduced clinical events among those who
received adenosine at either dosage; 2) adenosine at 70 g/kg/
min was associated with a statistically significant reduction
in SPECT infarct size compared with placebo; 3) there was
a significant correlation between infarct size and clinical
events; and 4) the benefits of adenosine were amplified
when reperfusion therapy, given early in the course of
infarction, successfully achieved infarct-artery patency.
Adenosine infusion as an adjunctive approach to limit
infarct size deserves close consideration because its use has
proved to be more encouraging than the vast array of
previous similar efforts.
COMMENTARY
This large multicenter trial examined adjunctive adenosine
combined with reperfusion therapy for acute MI. The
primary end point was time from randomization to the first
occurrence of CHF. Two adenosine doses were compared
with the placebo. The primary end point was reduced by
11% in the adenosine therapy groups, which was not
significant statistically. The primary end point was noted to
be significant for the subgroup that received adenosine and
was also reperfused. Secondary end points included a
substudy using SPECT thallium to measure infarct size.
Infarct size was decreased by more than one-quarter only in
patients who received high-dose adenosine but not in those
who received low-dose adenosine.
Previous efforts to improve infarct therapy outcomes
using adjunctive therapy such as magnesium have initially
appeared promising and then failed to achieve efficacy in
mega-trials. The results of therapy with adenosine seem
somewhat encouraging in this trial but have yet to achieve
the results necessary to establish this therapy as routine
practice. Adenosine as an adjunct remains attractive because
of its simplicity and relative lack of toxicity.
A fundamental problem in adjunctive pharmacotherapy
for reperfusion is the finding in early animal studies, with
agents such as beta-blockers and calcium-channel-blocking
agents, that therapy is most efficacious when initiated before
the onset of coronary occlusion. Initiating therapy before
the onset of infarction is rarely possible. The bar that
adjunctive therapies such as adenosine have to clear remains
high.
TED E. FELDMAN, MD, FACC
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Coronary Artery Stenting: A 1,000-Patient Prospective
Randomized Controlled Trial Comparing a Predilation With
a No-Predilation Strategy
KEITH D. DAWKINS, MD
WESSEX CARDIAC UNIT, SOUTHAMPTON, UNITED KINGDOM
Background. The Tetra Randomised European Direct
Stenting Study (TRENDS), a 1,000-patient randomized
controlled trial, evaluated the ACS MultiLink TETRA™
coronary stent system for the treatment of patients with
both de novo and restenotic native coronary artery lesions.
Methods. The trial, conducted at 46 centers in Europe and
Brazil, compared a predilation strategy (n  499) versus a
no-predilation (direct) approach (n  501) for elective stent
implantation. Inclusion criteria included angina, planned
stenting of single de novo or restenotic lesions in native
coronaries (multivessel procedures, one lesion per vessel,
were allowed;90% of patients had single-vessel disease), a
target-vessel diameter of 2.75 to 4.25 mm and length of up
to 18 mm by visual analysis, and target lesions of at least
70% stenosis. Excluded were patients with acute myocardial
infarction (MI) within the previous 24 h and those with
unprotected left main lesions, lesions involving a significant
side branch, severe calcification, periprocedural intravascular
ultrasound, or total occlusions. The primary end point was
major adverse cardiac events (MACE) at 30 days: a com-
posite of death, MI (with or without ST-segment eleva-
tion), and target-vessel revascularization. Intention-to-treat
secondary analyses included number of stents used, total
procedure time, fluoroscopy time, contrast volume, hospi-
talization time, six-month MACE, and binary restenosis
rate at six months. Results. Procedurally, there was a
significantly greater prevalence of lesion-site thrombus and
moderately severe target-site calcification in the direct-
stenting group (p  0.03). Dilation pressures, the need for
postdilation or additional stents, fluoroscopy time, contrast
volume, and hospitalization time were all similar in the two
groups. Predilation was performed in 31 of the 541 stents
deployed in the direct-stenting group (5.7%) because the
stent could not otherwise cross the lesion. There were no
significant differences at 30 days in the rates of MACE or of
any type of event making up the composite end point.
Conclusions. Direct stenting is technically feasible in most
electively stented patients in everyday practice. This study
provided no evidence that direct stenting is associated with
an increase in MACE at 30 days. Failure of the direct-
stenting strategy is uncommon, in this study occurring in
only 5.7% of attempts.
COMMENTARY
The TRENDS trial addresses a clinically relevant question:
Is there any disadvantage to the frequently practiced tech-
nique of routine direct stenting of non-total coronary lesions
without severe calcification or major branch involvement. In
this randomized trial of 1,000 patients, the lesions assigned
to the primary stent group were more likely to be calcified
and contain thrombus than were traditionally dilated le-
sions. Despite this apparent chance adverse selection, there
were no differences in 30-day MACE for the two groups,
with only 5.8% of the direct stent group requiring predila-
tion.
Short-term (1-month) results were not adversely affected
by the more rapid and cost-saving strategy, particularly
when additional post-stent dilation was not required. Ulti-
mately, as shown in other studies, six-month results will be
important in confirming that direct stenting is also not
associated with an increased risk of restenosis.
GEORGE W. VETROVEC, MD, FACC
Heparin-Coated Stents in Small Coronary Arteries: Results of
the COAST Trial
MICHAEL HAUDE, MD
UNIVERSITY OF ESSEN, ESSEN, GERMANY
Background. The role of stenting, compared with balloon
angioplasty, for the treatment of symptomatic coronary
artery stenoses in small vessels, where both techniques are
less successful than in larger vessels, remains unclear. Also,
the value of heparin-coated stents in small coronary arteries
has not been documented. Heparin-coated stents were
developed to limit the risk of thrombotic complications
associated with coronary stenting, but their use has been
little studied since the widespread use of recently introduced
antiplatelet agents. Methods. A total of 605 patients at 21
centers with native coronary stenoses in vessels 2.6 mm in
diameter were randomized to three treatment arms: balloon
angioplasty or implantation with either a noncoated
JOSTENT FLEX (ST) or a heparin-coated JOSTENT
FLEX (H-ST). Inclusion criteria included current stable or
unstable angina, a target-lesion reference luminal diameter
of 2.0 to 2.6 mm by quantitative angiography. Excluded
were patients with acute myocardial infarction within the
last 24 h, severe heart failure or cardiogenic shock, or lesions
longer than 30 mm. The primary end point was minimal
luminal diameter (MLD) at six months; secondary end
points included technical success rate and restenosis rate,
event-free survival, and clinical events in-hospital and at 30
days, 250 days, and one year. All three groups received
aspirin 100 mg/day; the two stent groups also received
ticlopidine or clopidogrel for four weeks. Results. In the
balloon angioplasty group, 27% required crossover to stent-
ing because of recoil or flow-limiting dissections or threat-
ened closure. There were no significant differences among
the groups in rates of individual clinical events (Table 1).
Conclusions. Larger post-interventional MLD and short-
term gain were found in the two stent groups; at follow-up,
there was a borderline statistically significant MLD and net
gain difference in favor of the stent groups with surprisingly
similar late loss compared with the balloon-angioplasty
group; the findings did not indicate statistically different
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restenosis rates among the three groups, although the study
was underpowered to detect such differences; angiographic
results for balloon angioplasty were surprisingly good, even
with a 27% crossover rate; interestingly, short- and long-
term event-free survival was similar for all three groups; and
the heparin-coated stent did not show any angiographic or
clinically relevant benefit compared with the uncoated stent.
COMMENTARY
Despite the widespread acceptance of stenting for most
coronary lesion subsets, the routine use of stenting in small
vessels is less clearly established. The COAST trial com-
pares the use of balloon angioplasty in small vessels (2.0 to
2.6 mm diameter by quantitative coronary angiography)
with coronary stenting using either a heparin-coated stent
or an uncoated stent. The study involved 21 centers in
Europe and enrolled 605 patients into the three treatment
arms. As expected, the mean post-procedure MLD and
short-term luminal gain were significantly greater in both
stent-treated groups. At follow-up, the primary end point
parameter of six-month MLD was greater in both stent
arms compared with balloon angioplasty, although the
difference was of borderline significance (p  0.049). Mean
percent stenosis at follow-up and mean net luminal gain
were also significantly better with stenting. However, binary
restenosis was not different among the treatment groups,
and clinical outcomes were similar in all three groups.
Although 27% of balloon angioplasty patients required
crossover to stenting due to dissection or a suboptimal
result, the overall results with balloon angioplasty of 32%
binary restenosis and 84% event-free survival were quite
good and were comparable to the results in both stent
groups. In addition, the heparin-coated stent conferred no
advantage for early or late clinical outcome or angiographic
results compared with the uncoated stent in these small
vessels.
It is perhaps not surprising that passive coating of a stent
with an antithrombotic agent such as heparin would have no
effect in prevention of restenosis. However, it does appear
that there is still a role for balloon angioplasty alone in the
treatment of small vessels, with use of provisional stenting
when needed for a suboptimal result.
MICHAEL J. COWLEY, MD, FACC
Atherectomy Before MULTI-LINK® Improves Luminal
Gain and Clinical Outcomes (AMIGO): A Comparison of
Coronary Stenting With or Without Adjunctive Directional
Coronary Atherectomy
ANTONIO COLOMBO, MD, FACC,
ON BEHALF OF THE AMIGO INVESTIGATORS
CENTRO CUORE COLUMBUS AND
SAN RAFFAELE HOSPITAL, MILAN, ITALY
Background. Previous studies have shown that acute an-
giographic minimal luminal diameter (MLD) and residual
stenosis are strong determinants of a favorable outcome
after coronary intervention. When stenting alone is applied
to complex lesions, results may not be as favorable as results
are with noncomplex lesions due to large plaque burden.
The addition of directional coronary atherectomy (DCA) to
stenting may reduce the involved plaque volume and thereby
increase luminal gain and lower the subsequent clinical
event and angiographic restenosis rates. Methods. We
randomized 753 patients with de novo and restenotic native
coronary lesions to stenting (single-vessel only) with (n 
381) or without (n  372) adjunctive DCA and followed
them up for 12 months. The two groups did not differ with
respect to baseline and preprocedure angiographic charac-
teristics. Results. The DCA/stent patients had a mean
post-DCA residual stenosis of 32.0%; only 21.5 % of the
patients had a post-DCA residual stenosis 20% (optimal
DCA). Mean postprocedure residual stenosis was 1.2% in
the DCA/stent group and 4.9% in the stent-only group
(p  0.0001). The 30-day composite rate of death, Q-wave
infarction, or target-lesion revascularization for DCA/stent
was 1.6% versus 1.1% for stent only (NS). Follow-up
angiographic binary restenosis rates were not significantly
different (24.1% for DCA/stent vs. 19.6% for stent only). At
two participating centers where optimal DCA was more
consistently practiced, the binary restenosis rates were 14%
Table 1. COAST Trial Outcomes
Results Balloon Angioplasty ST H-ST p Value
Follow-up available (N) 195 196 197
Mean MLD postprocedure (mm) 2.05 2.17 2.18 0.005
Acute gain (mm) 1.24 1.41 1.42  0.0001
Mean MLD follow-up (mm) 1.34 1.47 1.45 0.049
NS*
Mean % stenosis follow-up 42 36 38 0.038
Mean net gain (mm) 0.55 0.72 0.69 0.012
NS*
Binary restenosis rate (%) 32 25 30 NS
Event-free survival 250 days (%) 84 88 88 NS
*ST vs. H-ST.
H-ST  heparin-coated JOSTENT FLEX; MLD  minimal lumen diameter; ST  noncoated JOSTENT FLEX.
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for DCA/stent (50 lesions) versus 32% for stent only (47
lesions). This led us to analyze the data by separating
patients with optimal from those with suboptimal DCA.
Among patients at all trial centers, the binary restenosis
rates were 16.2% for optimal DCA/stent and 31.8% for
suboptimal DCA/stent (p  0.01). Suboptimal DCA/stent
emerged as a significant risk factor for binary restenosis in
multivariate analysis when compared with either optimal
DCA/stent or stent only (p  0.01). Conclusions. There
were no significant differences between DCA/stent and
stent only in clinical-event or angiographic restenosis rates;
this trial failed to show superiority of DCA/stent over stent
only. The stent-only binary restenosis rate of 19.6%, com-
pared with a hypothesis assumption of 30%, suggests that
the lesions were too favorable. Optimal DCA was achieved
in about one-fifth of lesions. At centers that more consis-
tently achieved optimal DCA and where complex target
lesions were more prevalent, DCA/stent appeared superior
to stenting alone. Therefore, we continue to perform DCA
with stenting for selected lesions.
COMMENTARY
The potential role of coronary debulking using DCA to
improve outcomes with coronary intervention has been the
subject of a number of clinical trials. Earlier studies of DCA
compared with balloon angioplasty alone were unable to
show improved follow-up clinical outcomes despite better
initial angiographic results. Subsequent studies comparing
“optimal” DCA with balloon angioplasty were associated
with improvement in certain follow-up parameters, such as
angiographic restenosis, but without clear benefit in clinical
outcomes.
The AMIGO trial was designed to show the superiority
of DCA followed by stenting over coronary stenting alone.
The study enrolled 753 patients who were randomized to
receive DCA or no DCA followed by treatment with a
MULTI-LINK® stent at 43 U.S. and European centers.
Patients were evenly matched for baseline characteristics.
Reference vessel size was approximately 3 mm, and nearly
60% of lesions were considered complex (American Heart
Association/American College of Cardiology lesion class B2
or C). In this trial, the final angiographic percent stenosis
was significantly less with DCA (1% vs. 5%), and the
30-day complication rates were similar and low (1.6% vs.
1.1%) in both groups. The primary end point of binary
angiographic restenosis at follow-up was not significantly
different (24% vs. 19.6%). Clinical event rates were also
comparable.
Review of DCA results in the study showed that “opti-
mal” DCA (defined as 20% residual stenosis prior to
stenting) was achieved in only 21.5% of patients. In a
subgroup analysis involving approximately 100 lesions from
two centers in which optimal DCA was more consistently
achieved, the binary restenosis rate was lower in the DCA
group. However, in the overall study population, the occur-
rence of suboptimal DCA followed by stenting was a
significant predictor of higher angiographic restenosis rates
than stenting alone (p 0.01). Although subgroup analyses
should be viewed with caution, it appeared that suboptimal
DCA was associated with a negative effect on the restenosis
rate compared with both optimal DCA and no DCA.
The concept of coronary plaque debulking as a method to
improve outcomes with coronary intervention has been an
attractive premise that has been difficult to validate in
clinical practice. The AMIGO trial does not strengthen the
case for routine debulking in this era of nearly universal
coronary stenting.
MICHAEL J. COWLEY, MD, FACC
Safety and Feasibility of a Tacrolimus-Coated Drug-Eluting
Stent: Short- and Mid-Term Results of Both the PRESENT
and EVIDENT Trials
EBERHARD GRUBE, MD, PHD, FACC
HEART CENTRE SIEGBURG, SIEGBURG, GERMANY
Background. Local delivery of immunosuppressive or anti-
proliferative agents using a drug-eluting stent can inhibit
in-stent restenosis, providing both a biological and mechan-
ical solution to an old problem. Animal trials have shown
that tacrolimus (FK 506), an immunosuppressive and anti-
inflammatory macrolide, specifically reduces the reactive
smooth-muscle-cell proliferation frequently associated with
coronary interventions but does not noticeably affect endo-
thelial cell proliferation. The prolonged in vivo kinetics of
FK 506 is caused by the agent’s lipophilicity and tissue-
binding effects. A tacrolimus-eluting stent is available as a
nanoporous ceramic-coated coronary stent (drug dosage,
3.75 g/mm of length) as well as a polytetrafluoroethylene-
covered stent graft for use in saphenous vein grafts (22
g/mm of length). Methods. We enrolled patients in two
separate nonrandomized single-dose phase-I safety studies
with similar protocols. The Preliminary Safety Evaluation
of Nanoporous Tacrolimus Eluting Stents (PRESENT)
trial included patients with single, de novo native-vessel
target lesions, 30 of whom received the tacrolimus-eluting
coronary stent and 30 of whom received the same ceramic
stent without active drug. In the Endovascular Investigation
Determining the Safety of New Tacrolimus-Eluting Stent
Grafts (EVIDENT) trial, 15 patients with single, de novo
vein-graft lesions received the tacrolimus-eluting coronary
stent graft. Stent implantation was guided by intravascular
ultrasound in both studies. All patients received either
clopidogrel or ticlopidine for six months and aspirin for 12
months; glycoprotein IIb/IIIa receptor inhibitors were used
only if clinically indicated. Results. Safety was defined as
freedom from the primary end point of major adverse
cardiac events (MACE) at 30 days, a goal reached by all of
the four EVIDENT and the 18 PRESENT patients whose
data were available for analysis.
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COMMENTARY
Dr. Grube and colleagues report preliminary data on ta-
crolimus (FK 506), an agent that in animal studies reduces
smooth-muscle-cell proliferation without effect on the en-
dothelial cell proliferation. The EVIDENT and
PRESENT trials are separate, single-dose, nonrandomized
studies of two types of tacrolimus-coated stents (a ceramic-
coated stent in the PRESENT trial; a PTFE-covered stent
in the EVIDENT trial). These trials enrolled limited
numbers of patients. The 30-day follow-up reported in the
abstract showed no MACE; during the presentation at the
American College of Cardiology 51st Annual Scientific
Session, it was noted that two patients in the PRESENT
study had subsequently returned with restenosis. Whether
this is a dose-dependent effect is unknown. Longer
follow-up of the complete data set will be necessary to
establish the safety and restenosis rates when using this
agent and these stent designs.
GEORGE W. VETROVEC, MD, FACC
LATE-BREAKING CLINICAL TRIALS I
Survival in Patients Presenting With Atrial Fibrillation:
The Atrial Fibrillation Follow-Up Investigation of Rhythm
Management (AFFIRM)
D. GEORGE WYSE, MD, PHD, FACC,
AND THE AFFIRM INVESTIGATORS
UNIVERSITY OF CALGARY, ALBERTA, CANADA
Background. Atrial fibrillation (AF) is a common arrhyth-
mia associated with increased risk of stroke or death.
Treatment can consist of either antiarrhythmic drugs to
maintain sinus rhythm (SR) (rhythm control) or ventricular
rate-controlling drugs that allow AF to persist or recur (rate
control). Both strategies use anticoagulation. It has not been
known whether one strategy is superior to the other.
Methods. The AFFIRM study compared the two treat-
ment strategies in 4,060 anticoagulant-eligible patients who
had at least 6 h of AF within the past six months, including
at least one episode documented by electrocardiogram
within the past 12 weeks. They were also required to have
one or more risk factors for stroke or death, including age
65, congestive heart failure, hypertension, poor left ven-
tricular function, large left atrium, diabetes, or prior stroke
or transient ischemic attack. Initial therapy in the rate
control arm (n  2,027) consisted of digoxin (51%),
beta-blockers (49%), and/or calcium-channel-blockers
(41%), often in combinations. Initial therapy in the rhythm
control arm (n 2,033) included amiodarone (39%), sotalol
(33%), propafenone (10%), procainamide (6%), quinidine or
flecainide (5% for each), or either disopyramide or mori-
cizine in the remainder. Many drug changes occurred
during follow-up, and nonpharmacologic therapies were
used in only a few patients. Results. The prevalence of SR
was 60% to 80% of patients in the rhythm control arm and
30% to 50% of patients in the rate control arm over a
five-year period. The prevalence of successful rate control
(defined by protocol) over a five-year period was 60% to
80% of patients in that arm. Prevalence of warfarin use was
higher in the rate control arm (86% vs. 69% at 5 years).
Crossover to the other management strategy occurred in
more rhythm control patients than rate control patients over
a five-year period (p  0.0001), with the crossover rate
reaching 35% and 12% for the two respective groups.
All-cause mortality, the primary end point, reached 24% in
the rhythm control arm and 21% in the rate control arm at
five years (p 0.058). The rates for the secondary end point
of death, disabling stroke or anoxic encephalopathy, major
bleeding, or cardiac arrest at five years were 29% and 28%
for the two respective groups (p  0.283). There were no
significant differences between the groups with respect to
indicators of functional status (6-min walk, New York
Heart Association functional class, Canadian Cardiovascu-
lar Society angina class) or quality of life. Most strokes in
both groups occurred in patients not taking warfarin or with
a subtherapeutic INR. Hospitalization was more common
in the rhythm control group, and this has implications for
cost. Conclusions. The AFFIRM trial has shown that
rhythm control does not offer a survival benefit or an
improvement in the quality of life or functional status when
compared with rate control. Rate control is an acceptable
primary therapy in such patients and may have some
advantages. Anticoagulation should not be stopped in these
patients.
COMMENTARY
The AFFIRM trial results provide important data relevant
to the management of patients with AF. Traditionally, there
had been a strong bias, at least among cardiologists, toward
treatment strategies aimed at restoring and maintaining SR
when patients present with AF. Physicians and patients
both were likely to attribute any symptoms they experienced
as being due to the arrhythmia and believed that the risk of
stroke and death could be minimized if SR were restored
and maintained. These clinical impressions had, however,
never been adequately examined in a clinical trial. The
AFFIRM trial was large enough to address these questions.
The study shows that, at least with currently available
pharmacologic therapy, there is no distinct a priori advan-
tage associated with a rhythm control strategy. Over a large
group of patients, symptoms were equally well managed by
careful rate control. Continuation of anticoagulant therapy
appears to be indicated even if a rhythm control strategy is
successfully implemented.
The AFFIRM trial data are likely to result in several
revisions to the current guidelines for AF management. A
decision on rate control or rhythm control should now be
based on a patient’s response to the initial therapy. Either
option is an acceptable first choice. Extensive attempts to
maintain SR are rarely indicated. Anticoagulation should be
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continued in patients with risk factors for stoke even if SR
is apparently maintained.
JOHN P. DIMARCO, MD, PHD, FACC
The Effect of Short-Term Treatment With Azithromycin on
Recurrent Ischemic Events in Patients With Acute Coronary
Syndrome: The AZACS Trial
BOJAN CERCEK, MD, FACC
CEDARS-SINAI MEDICAL CENTER, LOS ANGELES, CALIFORNIA
Background. There is a high rate of ischemic events within
six months after an initial episode of acute coronary syn-
drome (ACS). In addition, vascular inflammation leading to
intracoronary plaque rupture and thrombosis may in large
part be due to infection by Chlamydia pneumoniae or other
pathogens. Previous studies have suggested that treatment
with azithromycin or roxithromycin, antibiotics with activ-
ity against C. pneumoniae, can be associated with reduced
vascular inflammation and risk of ischemic events. The
AZACS study tested the hypothesis that the addition of
azithromycin to standard therapy shortly after presentation
with ACS reduces the risk of recurrent ischemic events and
death during the ensuing six months. This is the first
large-scale double-blind, placebo-controlled clinical study
evaluating treatment with macrolide antibiotics in patients
with ACS. Methods. We randomized 1,439 patients with
unstable angina or acute myocardial infarction (MI) at seven
centers to either azithromycin (500 mg orally on the first
day, followed by 250 mg daily for the following four days)
(n  716) or placebo (n  723). The primary end points
were death, cardiac arrest, nonfatal MI, or recurrent myo-
cardial ischemia requiring revascularization over six months
after discharge. There were no differences in the baseline
characteristics and treatment strategies between the two
groups. Six-month follow-up data were available for 702
patients in the active-therapy group and 710 patients in the
control group. There were no differences in their use of
anti-ischemic or other cardiac drugs. Results. Overall, the
primary end point event rate was 12.6% in the placebo
group and 12.3% in the azithromycin group (RR 0.98, 95%
CI 0.74 to 1.28). The rates of the individual end points of
death, nonfatal MI, or revascularization were not statisti-
cally different after six months. There was no significant
difference in the secondary end point of unstable angina or
congestive heart failure; nor, in subgroup analysis, were
rates for these end points different for patients enrolled
with acute MI or with antibodies to C. pneumoniae.
Conclusions. We conclude that in patients admitted
with ACS, short-term treatment with azithromycin did
not reduce the subsequent occurrence of ischemic events
or death over six months; and the results of treatment
with azithromycin were no different in patients with or
without with antibodies to C. pneumoniae.
COMMENTARY
The AZACS trial, the first large antibiotic study (n 1,412
patients) in the setting of ACS, attempted to confirm (or
refute) a large apparent treatment effect of a short course of
antibiotics as reported earlier in a smaller (n  202)
Argentine trial (ROXIS; Gurfinkel E, et al., Lancet 1997;
350:404–7). The four-day treatment regimen of azithromy-
cin did not reduce the primary composite end point of
death, nonfatal MI, or revascularization after six months
(p  0.77) in AZACS, nor were any of a number of
secondary end points or subgroups benefited. A small, early
separation of time-to-event curves was visually apparent, but
the curves came together and then crossed two months after
the four-day treatment course ended. Thus, if a role for
antibiotic therapy exists and is to be established in the
setting of ACS, a longer course of treatment or a different
antibiotic will need to be tested (see also Commentary on
WIZARD).
JEFFREY L. ANDERSON, MD, FACC
Weekly Intervention With Zithromax for Atherosclerosis
and Its Related Disorders: Preliminary Results of the
WIZARD Study
CHRISTOPHER M. O’CONNOR, MD, FACC
DUKE UNIVERSITY MEDICAL CENTER,
DURHAM, NORTH CAROLINA
Background. Epidemiologic studies link antibodies to
Chlamydia pneumoniae with coronary disease. The organism
has been found in 60% of atherosclerotic plaques. Animal
models suggest that infection by certain pathogens can be
followed by the initiation and progression of early plaque
formation. Furthermore, the pathogenesis of arterial C.
pneumoniae infection is associated with an inflammatory
condition that is consistent with atherogenesis. The clinical
impact of treating arterial infection by C. pneumoniae can be
assessed only in large clinical trials. The objective of the
WIZARD trial was to determine whether therapy with the
antibiotic azithromycin can prevent the recurrence of coro-
nary heart disease in adults with a history of acute myocar-
dial infarction (MI) longer than six weeks previously and
elevated titers to C. pneumoniae antibodies. Methods. Ex-
cluded were patients with a chronic condition that requires
antibiotic therapy and patients who have had a revascular-
ization procedure within the previous six months. The
patients were randomized to receive azithromycin (600 mg
every day for three days, then 600 mg every week for 11
weeks) (n  3,879) or placebo (n  3,868). The primary
end point was a composite of all-cause mortality, recurrent
MI, myocardial revascularization, and hospitalization for
angina. The patient groups had similar baseline demo-
graphic and clinical features, except for a greater history of
coronary heart disease in the active-therapy group: 33%
versus 31% in the control group (p  0.05). They also had
similar usage of cardiovascular medications at baseline.
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Results. Over a follow-up of 48 months (median, 2.1
years), there was no significant difference between the two
groups in the rate of the primary end point; nor was there a
significant benefit from azithromycin for any of the primary
end point components or for any patient subgroup by
baseline cardiac risk factors such as hypertension, diabetes,
or hypercholesterolemia. There was no benefit in patients
who were either positive or negative for C. pneumoniae
antibodies. Conclusions. We conclude that short-term
azithromycin therapy was safe and well tolerated, but we
found no evidence that it conferred a benefit for the primary
end point, whether in the presence of C. pneumoniae
antibodies or not. A post-hoc analysis suggested a possible
early treatment benefit that was not sustained over the total
observation period.
COMMENTARY
As the first antibiotic megatrial (N  7,747 patients) for
coronary artery disease (CAD), WIZARD is of great
interest. Overall, this is a negative study (hazard ratio 
0.93, p  0.23), confirming the lack of a meaningful
long-term clinical benefit of a three-month course of
azithromycin in patients with stable CAD. This result is
similar to that reported earlier in the smaller (N  302)
ACADEMIC trial (Muhlestein JB, et al., Circulation 2000;
102:1755–60) and contrary to the apparent, dramatic treat-
ment benefit in an initial British pilot study (Gupta S, et al.,
Circulation 1997;96:404 –7). However, a secondary
treatment-by-time analysis of WIZARD leaves a ray of
hope for antibiotic therapy: at six months, the secondary end
point of death/MI was reduced by one-third (relative risk,
0.67, 95% CI 0.48 to 0.94). Thereafter, differences between
treatment groups gradually diminished, suggesting a tran-
sient and cytostatic (rather than cytocidal) effect of the
three-month course of azithromycin. This secondary anal-
ysis heightens interest in Azithromycin and Coronary
Events Study, which is testing one year of azithromycin, and
Pravastatin or Atorvastatin Evaluation and Infection Ther-
apy, which is testing another, potentially more cytocidal
antibiotic, gatifloxacin.
JEFFREY L. ANDERSON, MD, FACC
The Integrilin and Enoxaparin Randomized Assessment of
Acute Coronary Syndrome Treatment (INTERACT) Trial
SHAUN G. GOODMAN, MD, FACC
ST. MICHAEL’S HOSPITAL, TORONTO, CANADA
Background. Current management of patients with high-
risk non–ST-segment elevation acute coronary syndromes
(NSTE ACS) generally incorporates glycoprotein IIb/IIIa
inhibition. Recently, the low-molecular-weight heparin
(LMWH) enoxaparin has been demonstrated to be superior
to unfractionated heparin (UFH) in two large trials. The
safety and efficacy of combination IIb/IIIa inhibitor and
LMWH therapy has yet to be determined and was the
purpose of the INTERACT trial. The primary objective of
the randomized, open-label study was to evaluate the
incidence of major bleeding in this clinical setting in
patients receiving either LMWH and UFH. Its secondary
objectives were to assess the incidence of ischemic ST-
segment shifts during continuous electrocardiographic
(ECG) monitoring and of clinical ischemic events, includ-
ing death and myocardial (re)infarction (MI). Methods.
Randomized patients at 54 centers had high-risk NSTE
ACS with resting angina within the past 24 h and ST-
segment depression (0.1 mV) or transient (20 min)
elevation (0.1 mV) in 2 contiguous leads, or troponin
rise to 3 times reference level or creatine kinase-MB
greater than normal. All patients received aspirin and
eptifibatide (180 g/kg bolus followed by 2.0 g/kg/min
infusion for 48 h). They received enoxaparin 1 mg/kg SC
twice daily (n  380) or UFH 70 U/kg bolus  15 U/kg/h
continuous infusion (n  366), titrated to an aPTT of 1.5
to 2 times control (50 to 70 s) for 48 h. All patients
underwent baseline, 48, and 96 h 12-lead ECG and two
consecutive 48-h 7-lead (3 channel) continuous ECG.
Safety end points included major and minor bleeding
events. Efficacy end points consisted of clinical ischemic
events as well as the frequency of recurrent ischemia on
continuous ECG in the first 48 h and in the subsequent
48 h after drug discontinuation. Thirty-day death, MI or
re-MI, severe recurrent ischemia requiring urgent revascu-
larization, and recurrent ischemia with ECG changes were
also measured. Results. Frequency and time to angiography
and revascularization were similar in the two groups. The
respective rates of major non– coronary bypass–related
bleeding for the enoxaparin versus UFH groups were 1.1%
versus 3.8% (p  0.014) at 48 h and 1.8% versus 4.6% (p 
0.030) at 96 h. The rates of minor bleeding at 96 h were
32.5% and 24.9%, respectively (p  0.024). Ischemia
developed by ECG within 48 h in 14% of the enoxaparin
group and 25.1% of the UFH group (p 0.0002), and from
48 to 96 h in 12.7% and 25.9%, respectively (p  0.0001).
The 30-day composite rates of death and MI or re-MI were
5% and 9% (p  0.031); of death and MI or re-MI, or
recurrent ischemia were 13.5% and 16.2% (p  0.30); and
of death, MI or re-MI or recurrent ischemia including ECG
changes were 8.4% and 12.6% (p  0.064), respectively.
Conclusions. In summary, enoxaparin when compared
with UFH in these patients, both with eptifibatide, was
associated with a lower rate of major bleeding, higher rate of
minor bleeding, lower rate of death or infarction, and lower
rate of ischemia during and shortly after treatment. The
trial, therefore, suggests that in high-risk NSTE ACS
patients who receive eptifibatide, enoxaparin provides sig-
nificantly better safety and efficacy than does standard UFH.
COMMENTARY
The randomized INTERACT trial compares the use of
LMWH with UFH in conjunction with the platelet glyco-
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protein inhibitor eptifibatide. Low molecular weight hepa-
rin in the form of enoxaparin was given 1 mg/kg subcuta-
neously twice daily versus a 15 U/kg/h UFH infusion.
The primary end point of major bleeding was reduced
significantly from 4.6% with UFH to 1.1% with LMWH.
Minor bleeding was similar in the two groups (24.9% vs.
32.4%) at 96 h. Ischemic events at 96 h were decreased from
24.9% in the UFH group versus 12.7% in the LMWH
group.
The diminution of both major bleeding and ischemic
events suggests that the frequency of both under-
anticoagulation and over-anticoagulation may be reduced by
LMWH. In conjunction with this platelet glycoprotein
inhibitor, overall ischemic events were diminished by
LMWH in the INTERACT trial, and the safety of
LMWH was clearly demonstrated.
TED E. FELDMAN, MD, FACC
LATE-BREAKING CLINICAL TRIALS II
Improved Survival With Prophylactic Implantable
Cardioverter-Defibrillator Therapy in Patients With Prior
Myocardial Infarction and Reduced Left Ventricular Ejection
Fraction: The MADIT-II Trial
ARTHUR J. MOSS, MD, FACC
UNIVERSITY OF ROCHESTER, ROCHESTER, NEW YORK
Background. The MADIT-II trial evaluated the effect of
implantable cardioverter-defibrillator (ICD) therapy on sur-
vival in 1,232 patients of any age who had prior myocardial
infarction (MI), had a left ventricular ejection fraction
(LVEF) of 30%, and had not been required to undergo
electrophysiologic testing for risk stratification. Excluded
were patients in New York Heart Association (NYHA)
class IV heart failure (HF) and those who had experienced
an MI within the past one month or undergone coronary
bypass surgery within the past three months. Methods. A
two-sided sequential design was used, with all-cause mor-
tality as the end point. The patients were randomized in a
3:2 ratio to receive an ICD (n  742) or to conventional
management without an ICD (n  490); the groups were
similar in baseline demographic and clinical characteristics.
The mean LVEF in each arm of the trial was 23%.
Medication usage at the last follow-up was similar in the
two groups, with more than 70% in both receiving
angiotensin-converting enzyme inhibitors, beta-blockers,
and diuretics. Results. The trial, initiated July 8, 1997, was
halted on November 20, 2001, by the Data Safety and
Monitoring Board because of a significant survival benefit in
the ICD group. After an average of 21 months of follow-up,
mortality in the ICD and conventional-therapy groups were
14.2% and 19.8%, respectively (p  0.016). The hazard
ratio for all-cause mortality was 0.69 (95% CI, 0.51 to 0.93),
indicating a 31% decrease in mortality with ICD therapy.
This benefit of device therapy survival was similar in patient
subgroups by age, gender, LVEF, NYHA class, QRS
duration, and other parameters. Analysis of mortality events
by treatment arm showed a markedly lower rate of arrhyth-
mic death in the ICD group: 27 events (3.6% of the total
group) versus 46 events in the conventional-therapy group
(9.4% of the total). Conclusions. This finding suggests that
the reduction in all-cause mortality in the ICD group is
consistent with the ICD as the protective mechanism. We
conclude that in patients with prior MI and moderate to
severe left ventricular (LV) dysfunction, the use of ICD
prophylaxis in addition to conventional medical therapy
results in a significant reduction in mortality compared with
conventional medical therapy alone.
COMMENTARY
The use of an ICD has shown to be effective in reducing risk
of death in survivors of cardiac arrest (secondary prevention)
as well as high-risk patients with coronary artery disease
(CAD) and depressed LV function with additional markers
of augmented arrhythmia risk such as nonsustained ventric-
ular tachycardia or inducible ventricular tachycardia on
electrophysiologic testing. The MADIT-II trial tested the
broader extension of the use of an ICD to high-risk patients
with prior MI depressed LV function (EF 30%) but
without the use of Holter monitoring or electrophysiologic
testing to refine the risk of arrhythmic death.
MADIT II is a high-quality study that clearly extends the
life-saving benefits of the ICD to the broader population
post-MI patients with LV dysfunction but without marked
HF and without a major selection for arrhythmic risk. By
extending the use of ICDs to this broader population,
implications for both public health and financial allocations
are immense. Since not all patients with stable CAD
depressed LV function die a sudden ICD-preventable
arrhythmic death, we are going to need more information
from the investigative community on the best ways to utilize
the MADIT II results within the confines of health care
budgets. Information regarding nonfatal events, such as the
development of HF, recurrent MI, other hospitalizations,
cost–benefit analyses, and quality of life, from MADIT-II
and other ongoing studies will be needed for the optimal
implementation of the important scientific advance gained
from MADIT II.
MARC A. PFEFFER, MD, PHD, FACC
Effects of the Endothelin Receptor Antagonist Bosentan on
Morbidity and Mortality in Patients With Chronic Heart
Failure: The ENABLE 1 and 2 Trial Program
MILTON PACKER, MD, FACC
COLUMBIA PRESBYTERIAN MEDICAL CENTER,
NEW YORK CITY, NEW YORK
Background. Endothelin-1 (ET-1) is a potent endogenous
vasoconstrictor capable of exerting a wide range of adverse
biological and pathophysiological effects in chronic heart
failure (HF). Antagonism of endothelin receptors has been
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shown to favorably influence cardiac remodeling and hyper-
trophy and to prolong life in experimental HF. Bosentan is
an oral dual endothelin (ETa/ETb) receptor antagonist that
has produced favorable hemodynamic effects in patients
with chronic HF and improved the clinical status of patients
in early small pilot studies. However, the long-term effects
of endothelin antagonism on the morbidity and mortality of
patients with chronic HF have not been evaluated. The
ENABLE (ENdothelin Antagonism with Bosentan for
Lowering of Events) trial program consisted of two identi-
cal, double-blind, randomized, placebo-controlled, concur-
rent trials conducted at 150 centers in Europe, Israel, and
Australia (ENABLE-1) and the U.S. and Canada
(ENABLE-2). Methods. The two trials enrolled 1,613
patients with New York Heart Association class IIIB to IV
ischemic or nonischemic HF, and a left ventricular ejection
fraction (LVEF) 35%, who had been hospitalized for
chronic HF within 12 months or had a 6-min walk distance
375 m. Patients were randomized to either bosentan
(62.5 mg twice daily, escalated in four weeks to a target dose
of 125 mg twice daily) (n  805) or matching placebo (n 
808), both added to conventional therapy, for a mean of
18.7 months. The trials continued until the prespecified
number of 600 primary morbidity/mortality events had been
observed. Results. For the primary end point of all-cause
mortality or hospitalization for chronic HF, the rates were
38.8% in the bosentan group and 39.7% in the placebo
group with a hazard ratio of 1.01 (p  0.9). For the
secondary end point of all-cause mortality, the rates were
19.9% and 21.4%, respectively, hazard ratio 0.94 (p 0.53).
In subgroup analysis, bosentan was not associated with a
significant benefit in either the primary or the secondary end
point by age, gender, ENABLE trial (1 or 2), LVEF,
functional class, etiology of HF, or use of beta-blockers at
baseline. Bosentan was associated with an increased risk of
worsening chronic HF in these studies, possibly the results
of an unexpected increase in fluid retention: bosentan-
treated patients showed early and sustained increases in
body weight and peripheral edema and decreases in hemo-
globin. In addition, as previously reported with higher
doses of bosentan, the use of low doses in this trial was
associated with an excess frequency of liver function
abnormalities, manifested primarily as increases in he-
patic transaminases that were rapidly reversible upon
discontinuation of therapy. Conclusions. Long-term
treatment with the endothelial antagonist bosentan did
not reduce the risk of death or hospitalization or the risk
of death alone in patients with chronic HF. This lack of
benefit may have been related to the early and sustained
development of fluid retention. Therefore, efforts to
minimize fluid retention, either with much more aggres-
sive use of adjunctive diuretics or perhaps lower doses of
bosentan, may help to identify the appropriate role of
endothelial antagonism in the treatment of HF.
COMMENTARY
The ENABLE study is another contribution to the rich
collection of large randomized clinical trials of medical
management in the world of HF. There were certainly
excellent theoretical reasons and experimental evidence to
indicate that the blocking of endothelin receptors should be
beneficial in HF, and smaller short-term clinical studies
revealed mixed results but were generally encouraging. This
definitive study, however, failed to show any improvement
in the primary or secondary end points when the endothelin
receptor antagonist bosentan was added to standard medical
therapy for HF. Importantly, there was also a negative
aspect to the study in that there was an increased incidence
of worsening HF observed in the bosentan-treated patients
soon after the initiation of therapy.
It is difficult to know whether more meticulous attention to
management of volume status after introduction of the drug
could have obviated the worsening HF that was observed. All
the patients were managed at experienced HF centers in the
U.S. and Europe, where excellent management would be
expected. It is also difficult to know whether the dose of
bosentan chosen for the study was the “optimal” dose. While
the dose was, in fact, considerably lower than that used in
earlier clinical trials, it is possible that even lower doses could
prove beneficial without the fluid retention side effects.
For the moment, the role of endothelin receptor antag-
onism in the therapy of HF remains uncertain.
SHARON HUNT, MD, FACC
Randomized Evaluation of Mechanical Assistance for
Treatment of Congestive Heart Failure (REMATCH):
Major Survival Benefit From Left Ventricular Assist Devices
for Patients Receiving Intravenous Inotropic Therapy
LYNNE WARNER STEVENSON, MD, FACC,
LESLIE MILLER, MD, FACC,
PATRICE DESVIGNE-NICKENS, MD,
DONNA MANCINI, MD, DEBORAH ASCHEIM, MD,
ALAN WEINBERG, MD, DALE RENLUND, MD,
RONALD OREN, MD,
STEVEN KRUEGER, MD, FACC,
MARIA COSTANZO, MD, FACC,
L. SAMUEL WANN, MD, FACC, NUALA RONAN, MD,
LOPA GUPTA, MD, FOR THE REMATCH
CARDIOLOGISTS
BRIGHAM & WOMEN’S HOSPITAL,
BOSTON, MASSACHUSETTS
Background. New therapies should be directed toward the
patients most likely to benefit. Left ventricular assist devices
(LVADs) as permanent therapy will have the greatest
impact on survival in those patients for whom heart failure
(HF) severity predicts early death during medical therapy
but does not compromise the postoperative course. Meth-
ods. Patients in REMATCH had New York Heart Asso-
ciation class IV symptoms with left ventricular ejection
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fraction (LVEF) 25% and were ineligible for transplan-
tation. Severity was further defined by a peak VO2 of12 to
14 ml/kg/min or an inability to wean intravenous inotropic
agents. The entire group was randomized to undergo
implantation with the HeartMate LVAD or to receive
optimal medical management from experienced HF cardi-
ologists. The latter management strategy focused on opti-
mization of oral therapy without inotropic infusions (i.e.,
“survival without suffering”). Results. The primary hypoth-
esis of REMATCH was that an LVAD would reduce
mortality by 33% over the trial’s two-year follow-up. As
previously reported, one-year survival in the LVAD arm was
51% versus 28% for optimal medical management, and the
two-year survival was 28% and 10%, respectively (p 
0.0015). In the current analysis, we attempted to identify a
subgroup of patients in the REMATCH trial who derived
the major survival benefit and meaningful quality of life
from the LVAD as destination therapy. Of the 129 patients
in REMATCH, 91 (71%) were receiving inotropic infu-
sions at baseline. Hypotension, low cardiac output, and
renal dysfunction were the most common reasons for
continuing inotropic infusions. The patients receiving ino-
tropic infusions at baseline had the same mean LVEF but
more severe HF than those not receiving inotropic infu-
sions, as indicated by lower mean systolic blood pressure
(99 mm Hg vs. 107 mm Hg, p  0.019), lower serum
sodium (134 mEq/l vs. 137 mEq/l, p 0.0008), and a trend
for higher pulmonary wedge pressure (p  0.06) despite
inotropic infusions. Among patients receiving intravenous
inotropes at baseline, survival at six months reached 58% in
the LVAD group versus 39% in the group receiving medical
management, and by one year the survival rates were 49%
and 22%, respectively (p  0.0016). By two years after
randomization of the patients receiving inotropic infusions,
24% of the LVAD group were still alive, and all patients in
the medical group had died. Quality-of-life measures in this
group showed more favorable outcomes in the LVAD group
at all time points, but because of small patient numbers in
the medical group the difference did not reach significance.
Among patients not receiving intravenous inotropic agents
at baseline, the survival rate at six months was 61% in both
the LVAD group and the group receiving optimal medical
management, at one year 56% and 40%, respectively, with-
out significant difference during the two-year period (p 
0.52). Conclusions. The major benefit of the LVAD as
destination therapy was observed in patients receiving ino-
tropic therapy at the time of randomization. The immediate
extension of currently successful LVAD technology to a
less-sick population would not be expected to confer a
benefit comparable to that shown in REMATCH. How-
ever, further improvement in outcomes is anticipated with
device modifications and other management strategies such
as the effective infection prophylaxis that has already de-
creased complication rates at programs in Salt Lake City
and Minneapolis. As device complications decrease, there
will be a benefit for a broader population. For the current
selection of candidates, the use of intravenous inotropic
therapy alone should not be viewed as a sufficient indication
for the LVAD as destination therapy; inotropic infusions
are frequently used in patients who do not require them and
who are frequently considered unweanable until they un-
dergo redesign of their other medical therapy at expert
centers. The urgent implications of this study are that we
need to use the imminent “incubation period” before allow-
ing multiple support devices to proliferate in order to better
understand the candidate population, particularly with re-
gard to the real and perceived need for inotropic support.
Furthermore, the identification of this population mandates
an increased attention to development of alternative thera-
pies for end-stage HF for patients who are not candidates
for devices. Such therapies should include better inotropic
therapy for symptom palliation and enhancement of hospice
therapies for those who face imminent mortality.
COMMENTARY
It is clear that, although heart transplantation provides an
excellent therapy to extend life and improve its quality for
patients with HF that is truly end-stage, the limited donor
supply restricts transplantation to making a quantitatively
small contribution to the considerable number of patients
who could benefit from it. It is clear as well that many
patients with end-stage HF have contraindications to heart
transplantation. Thus, there is a great need for alternatives
to allotransplantation of the heart.
This subset analysis of the previously published RE-
MATCH trial of permanent circulatory support with LVAD
technology in patients with end-stage heart disease who were,
mainly because of advanced age, considered ineligible for heart
transplantation provides important insight into the study data.
It reveals that the improved survival with LVAD use seen in
this study was really confined to the 70% of the group who
were truly inotrope dependent. This fact emphasizes the
danger in considering the extension of the LVAD technology
used in this study to a less-sick population. The survival rates
in the LVAD patient group in this study are so markedly
inferior to those expected after transplantation that it is difficult
to view the current generation of LVAD technology as a true
“alternative” to transplantation.
SHARON HUNT, MD, FACC
A Prospective, Blinded Trial of B-Type Natriuretic Peptide as a
Diagnostic Test for the Emergency Diagnosis of Heart Failure:
The Breathing Not Properly (BNP) Multinational Study
ALAN S. MAISEL, MD, FACC,
PETER A. MCCULLOUGH, MD, MPH, FACC
UNIVERSITY OF CALIFORNIA-SAN DIEGO
SCHOOL OF MEDICINE, SAN DIEGO VETERANS AFFAIRS
MEDICAL CENTER, SAN DIEGO, CALIFORNIA;
UNIVERSITY OF MISSOURI-KANSAS CITY
SCHOOL OF MEDICINE, TRUMAN MEDICAL CENTER,
KANSAS CITY, MISSOURI
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Background. The neurohormone B-type natriuretic pep-
tide (BNP) is released from ventricular myocytes in response
to wall tension caused by ventricular volume expansion and
pressure overload. Measurement of BNP has been approved
as an aid to the diagnosis of congestive heart failure (CHF).
In the prospective BNP Multinational Study, we sought to
determine the diagnostic utility of BNP in the emergency
department (ED) evaluation of dyspnea in a broad spectrum
of patients. Methods. A total of 1,586 patients who
presented to the ED with acute dyspnea as their primary
complaint upon arrival underwent measurement of BNP
with a point-of-care device. Patients with acute myocardial
infarction or renal failure as the cause of dyspnea were
excluded. Emergency physicians were asked to give a
blinded, pre-test probability of the diagnosis being CHF.
The gold standard for CHF was adjudicated by two inde-
pendent cardiologists, blinded to BNP results, who re-
viewed all clinical data and standardized CHF scores. The
primary end point was diagnostic accuracy. The analysis
used a Bayesian approach that took into account: 1) the a
priori pre-test probability from the ED clinician; 2) the
BNP test converted to a likelihood ratio through the range
of diagnostic values; and 3) a post-test probability generated
from these two values. The final diagnosis was CHF in 744
(46.9%), a history of CHF and left ventricular (LV) dys-
function but dyspnea due to noncardiac causes in 72 (4.5%),
and not CHF in 770 (48.5%). Median levels of BNP in the
patients with CHF as a final diagnosis were 600 pg/ml; in
those with LV dysfunction but a noncardiac cause of
dyspnea, 150 pg/ml; and in patients without CHF,
50 pg/ml (p  0.0001). Among the patients with a final
diagnosis of CHF, BNP levels varied significantly as a
function of New York Heart Association (NYHA) class; the
median BNP values for NYHA class I (n  18), II (n 
152), III (n  351), and IV (n  276) were 150, 250, 550,
and 900 pg/ml, respectively. At a cutoff of 100 pg/ml, BNP
had a diagnostic sensitivity of 90%, a specificity of 76%, a
positive predictive value of 79%, and a negative predictive
value of 89%. For the primary end point of diagnostic
accuracy, clinical judgment (with ED physicians required to
be at least 80% certain of a CHF diagnosis) achieved an
accuracy of 74.0%, the BNP test achieved an accuracy of
81.1%, and clinical judgment combined with the BNP test
achieved an accuracy of 81.6% (p  0.0001). In 43% of
cases, the ED physician was uncertain of the final diagnosis
(ED probabilities between 20% and 80%). In these cases, if
BNP at a cutoff of 100 pg/ml, clarified 75% of those cases,
leaving an absolute 11% of patients in whom there was
uncertainty, implying additional testing would be war-
ranted. Conclusions. The BNP test adds independent
diagnostic information to the traditional components of the
CHF evaluation (history, physical exam and chest X-ray).
Mean BNP values reflect functional class in patients with
heart failure (HF). In patients for whom the conventional
ED diagnosis of HF is equivocal, the use of BNP at a cutoff
of 100 pg/ml, will correctly classify 74% of cases. The
implications of this study are that BNP should be included
as a component in the initial diagnostic evaluation of
dyspnea, where it can play a role in confirming the clinical
diagnosis and, importantly, in improving diagnostic accu-
racy in the large proportion of cases where there is uncer-
tainty.
COMMENTARY
B-type natriuretic peptide is now accepted as an adjunctive
diagnostic test to confirm the presence of HF. This trial
represents an important step by investigators in assessing the
value of plasma BNP as an aid in the diagnosis HF in the
setting of the hospital ED. The value of the test lies mainly
in its negative predictive value, although increased plasma
BNP levels may help to identify patients with more ad-
vanced HF. Plasma BNP was more accurate than the
clinical judgment of the ED physician. The Breathing Not
Properly study confirms the utility of plasma BNP as an aid
in the diagnosis of HF. However, the design of the study
did not allow for a direct testing of whether BNP adds value
to clinical judgment, which is perhaps a more important
question in the “real world.” Patients with HF may have
intermediate plasma BNP levels when clinically stable or
only mildly symptomatic. Age, gender, and diastolic func-
tion can also alter plasma BNP levels. Normal levels and
very high levels are seemingly of greatest value. However,
the intermediate BNP values may possibly be used to guide
therapeutic decisions. There is already a suggestion that
BNP-guided therapy may be more beneficial to patients
than non–BNP-guided conventional therapy. However, this
hypothesis needs to be tested in a randomized controlled
trial.
GARY S. FRANCIS, MD, FACC
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Background. Endomyocardial biopsy remains the gold
standard for the detection of tissue rejection in patients with
transplanted hearts. However, the procedure is costly,
highly invasive, of limited accuracy, and can cause infection,
arrhythmias, or other complications. A sensitive and non-
invasive screening test for heart transplant rejection would
represent an advance. The rejection process is accompanied
by oxidative stress caused by increased mitochondrial pro-
duction of reactive oxygen species. Oxidative stress degrades
polyunsaturated fatty acids in membranes by lipid peroxi-
dation, which releases alkanes and methylalkanes, volatile
organic compounds (VOCs) that are excreted in the breath.
Methods. We evaluated a breath test for oxidative stress—
the breath methylated alkane contour (BMAC)—using a
proprietary breath VOC collection device as a screening tool
in heart transplant recipients at seven institutions prior to
their scheduled endomyocardial biopsy. We also collected
breath samples from healthy, age-matched normals. Collec-
tion of the 1,061 breath samples required approximately
2 min of each patient’s time. A site pathologist and two
reviewers independently scored biopsies for International
Society for Heart and Lung Transplantation (ISHLT)
rejection grade. Breath VOCs were analyzed by gas chro-
matography and mass spectroscopy, and the BMAC was
derived from alveolar gradients (relative abundance in
breath minus relative abundance in air) of C4-C20 alkanes
and monomethylalkanes. The BMAC results were com-
pared with the jointly agreed ISHLT scores, and VOC
markers of rejection were identified by discriminant analysis.
Results. The independent-reviewer biopsy results disclosed
645 patients (60.8%) with ISHLT rejection grade 0 (no
rejection) and 281 (26.5%) with grade 1 (mild) rejection, 93
(8.8%) with grade 2 (moderate) rejection, and 42 (4.0%) with
grade 3 (severe) rejection. Compared with the independent
reviewers, a biopsy reading by a site pathologist had a sensi-
tivity of 42.4% and specificity of 97.0% for grade 3 rejection.
Breath test results revealed nine VOCs whose levels repre-
sented markers of grade 3 rejection. In a predictive model, the
breath markers had a sensitivity of 78.6% and specificity of
62.4%; the cross-validated model had a sensitivity of 59.5%
and specificity of 58.8%. Thus, the breath test for markers of
oxidative stress was more sensitive but less specific for grade 3
heart transplant rejection than were biopsy readings by site
pathologists. The negative predictive value of the breath test
for grade 3 rejection was 97.3%, which was similar to that of a
biopsy reading by a site pathologist (97.5%) (i.e., in a patient
with a negative breath test, a biopsy contributes no additional
clinical information). Conclusions. Based on these findings, a
screening breath test could potentially reduce the number of
endomyocardial biopsies for heart transplant rejection by at
least one-half with no loss of diagnostic accuracy.
COMMENTARY
The “holy grail” in the surveillance for cardiac rejection in
heart transplant patients has always been the discovery of a
noninvasive, inexpensive, readily available, “low-tech” alter-
native to the use of the endomyocardial biopsy, a technique
that possesses none of these characteristics but is currently
considered the gold standard. The assay described in the
HARDBALL study is another in a long series of technol-
ogies that are candidates for replacing surveillance heart
biopsies, and it is certainly one of the most unusual, basically
being a breathalyzer test.
The study shows a surprising lack of consistency between
biopsy interpretation by the pathologist at the transplant
program site and the independent pathologist working with
the authors. It also shows that, although only 9 of 42
(independent pathologist–interpreted) biopsies with grade 3
rejection were predicted by the threshold level of volatile
organic compounds that the authors set for the breath
sample, the negative predictive value for grade 3 rejection
was 97.3%. These results are difficult to evaluate given the
disparity of pathology interpretation, and adoption of the
technology also awaits further investigation and correlation
with the presence or absence of concurrent patient illnesses,
such as hemodynamic compromise and infection, which
theoretically could decrease sensitivity and specificity of
anything that is a marker of oxidative stress.
SHARON HUNT, MD, FACC
LATE-BREAKING CLINICAL TRIALS III
Results of the InSync ICD Clinical Trial
JAMES B. YOUNG, MD, FACC
THE CLEVELAND CLINIC FOUNDATION, CLEVELAND, OHIO
Background. More than one-third of patients with
moderate-to-severe heart failure (HF) have ventricular dys-
synchrony, which leads to poor left ventricular (LV) func-
tion, limited exercise tolerance, and impaired quality of life
(QOL). The InSync ICD trial is a multicenter, double-
blind controlled study evaluating the safety and effectiveness
of cardiac resynchronization therapy (CRT) in patients with
advanced (New York Heart Association [NYHA] class III
to IV) systolic HF, LV ejection fraction 35%, ventricular
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dyssynchrony, and an indication for an implantable
cardioverter-defibrillator (ICD). Methods. A total of 362
such patients were implanted with an InSync model 7272
ICD with anti-tachycardia and biventricular pacing. Within
three to seven days, 186 patients were randomized to have
their implant control (their CRT unit) set to “on,” and 176
patients were randomized to have their CRT units set to
“off.” The ICD functions were continuously activated in all
patients. The primary safety end points included freedom
from ICD discharges and system and LV lead-related
complications. Primary effectiveness end points included
were QOL, NYHA class, and 6-min hallwalk distance.
Secondary end points included cardiopulmonary exercise
testing (peak VO2 and exercise time), neurohormonal vari-
ables, and the HF clinical composite response (incorporates
death, HF hospitalizations, NYHA class, and global self-
assessment into categories of “improved,” “unchanged,” or
“worsened” HF status). Results. At six months, mean QOL
scores had improved by 19 points in the CRT-on group and
by 10 points in the CRT-off group (p  0.0098); NYHA
functional class improved in 63% and 47%, respectively (p
0.028); mean peak VO2 had improved by 1.1 ml/kg/min in
CRT-on patients and had not changed in CRT-off patients
(p  0.05); mean total exercise time had changed by 58 s
and 26 s, respectively (p  0.001). The clinical composite
end points were improved, 55% for CRT-on patients and
40% for CRT-off patients; no change, 19% and 26%; and
worsened, 26% and 33% (p  0.038 for all differences
between treatment groups). There were no significant six-
month differences in 6-min hallwalk. Conclusions. In the
patients with moderate-to-severe HF, cardiac resynchroni-
zation therapy improved QOL, functional capacity, and
exercise tolerance and had an acceptable safety profile.
COMMENTARY
Device therapy has many potential applications in patients
with HF and LV dysfunction. Biventricular pacing may
improve HF symptoms and functional status by reversing
ventricular dyssynchrony. An ICD may decrease arrhythmic
death and, possibly, total mortality. Since device-to-device
interactions can be a source of potential problems whenever
two devices are used in the same patient, it would be
beneficial to have these functions combined in a single
device in appropriate patients with HF. The InSync ICD
trial is the first reported large trial of such a combined
device. All patients in the study had an indication for ICD
therapy, but their HF appears to have been somewhat less
severe than was the case in previous studies on CRT. There
was a consistent pattern toward improvement in HF status;
but, as in the trials of biventricular pacing alone, many
patients also improved even if the resynchronization was not
activated. Larger studies with long follow-up trials will be
needed to determine whether biventricular pacing provides
better survival than ICD therapy alone. It will also be
important to determine if the benefits are maintained in the
long term.
JOHN P. DIMARCO, MD, PHD, FACC
The 4E Study: Eplerenone, Enalapril, and
Eplerenone/Enalapril Combination Therapy in Patients With
Left Ventricular Hypertrophy
BERTRAM PITT, MD, FACC
UNIVERSITY OF MICHIGAN, ANN ARBOR, MICHIGAN
Background. Left ventricular hypertrophy (LVH) is asso-
ciated with significant increases in cardiovascular morbidity
and mortality in hypertensive patients. Activation of the
renin-angiotensin-aldosterone system plays an important
role in the pathophysiology of LVH. Although angiotensin-
converting-enzyme (ACE) inhibitors and angiotensin-II
receptor blockers and their combination fail to suppress
aldosterone over the long term, this may be accomplished by
aldosterone receptor blockers. These agents prevent LVH
progression and cardiac fibrosis in hypertensive patients
when used alone or in combination with an ACE inhibitor.
Methods. We conducted a double-blind, forced-titration
study comparing the efficacy and tolerability of eplerenone,
a selective aldosterone blocker, with the ACE inhibitor
enalapril and also with their combination. Patients with
diastolic blood pressure (BP) at least 90 mm Hg and
114 mm Hg and systolic BP 140 mm Hg and
200 mm Hg with echocardiographic LVH were random-
ized after a 14-day washout period to eplerenone only
200 mg/day (n 64), enalapril only 40 mg/day (n 71), or
eplerenone 200 mg/day plus enalapril 10 mg/day (n  67)
for nine months. After eight weeks, diuretics or amlodipine
were added as necessary. The primary end point was change
in left ventricular (LV) mass after nine months as assessed
by magnetic resonance imaging (MRI). Secondary end
points included changes in systolic and diastolic BP, urinary
albumin-creatinine ratio (UACR), and safety events. Re-
sults. The mean change in LV mass was 14.5 g for the
eplerenone-only group, 19.7 g for the enalapril-only
group, and 27.2 g for the combination-therapy group
(p  0.007 eplerenone-only vs. combination; p  0.05 for
all three groups vs. baseline). Blood pressure reductions
were statistically similar in the three groups. However,
UACR was significantly reduced in the combination group
(by 52.6%) as compared with the eplerenone-only group
(24.9%, p  0.001) and the enalapril-only group (37.4%,
p  0.038). Cough was significantly less common in the
eplerenone-only group (3.1%) than in the enalapril-only
group (14.1%, p  0.05); the rate of cough was 9.0% in the
combination group (NS). There were no significant differ-
ences in rates of hypotension, hyperkalemia, hypokalemia,
impotence, gynecomastia, menstrual abnormalities, or
breast pain. Thus, eplerenone was similar to enalapril in
reducing LV mass, BP, and UACR in patients with
hypertension; eplerenone plus enalapril reduced LV mass
and systolic BP significantly more than eplerenone alone;
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the combination of eplerenone and enalapril significantly
reduced UACR more than eplerenone or enalapril alone;
add-on BP medication was required significantly more often
in the enalapril group than in the eplerenone group; and all
treatments were safe and well tolerated, although signifi-
cantly more patients who received enalapril experienced
cough than those who received eplerenone. Conclusions.
Selective aldosterone blockade, with eplerenone alone or
combined with ACE inhibition, is effective for organ
protection and BP control in patients with essential hyper-
tension and LVH.
COMMENTARY
Eplerenone is a new highly selective aldosterone receptor
antagonist that is currently under study for the treatment of
hypertension and heart failure (HF). Eplerenone use results in
less gynecomastia than spironolactone. Because it acts in part
through a nuclear receptor, it is likely that it is altering
transcription of a number of genes, including those responsible
for the generation of nitric oxide. Preliminary studies suggest
that eplerenone reduces collagen turnover and myocyte size in
an experimental animal model of cardiomyopathy. In the 4E
Study, eplerenone was shown to reduce LV mass as measured
by MRI to nearly the same extent as enalapril. However, the
combination of enalapril and eplerenone dramatically reduced
LV mass over a period of nine months. Because BP reduction
was similar in the three arms, the data suggest that the
combination may provide benefit beyond that afforded by
simple improvement in loading conditions. The results of this
and other studies have produced in an increased awareness of
the role of aldosterone in the pathogenesis of hypertension and
HF. Eplerenone is also being studied in a large, randomized,
placebo-controlled trial in which it is being evaluated in
patients with acute myocardial infarction and HF. The results
of this mortality study should be known in the fall of 2002.
GARY S. FRANCIS, MD, FACC
The LIFE Trial: Cardiovascular Mortality and Morbidity in
the Losartan Intervention for End Point Reduction in
Hypertension Trial
BJO¨RN DAHLO¨F, MD
UNIVERSITY OF GO¨TEBORG AND
OSTRA UNIVERSITY HOSPITAL, GO¨TEBORG, SWEDEN
Background. No antihypertensive agent has shown a
uniquely greater benefit than any other in a primary com-
parison. Left ventricular hypertrophy (LVH) is a strong
independent risk indicator of cardiovascular (CV) morbidity
and mortality. Selective blocking of angiotensin II (A-II),
an important growth factor, might confer benefits beyond
blood pressure (BP) reduction. Methods. In the LIFE trial,
9,193 patients with essential hypertension (160 to
200 mm Hg systolic, 95 to 115 mm Hg diastolic; mean
174/98) and electrocardiographic LVH were randomized
prospectively and double-blind to losartan- or atenolol-
based therapy (A-II blockade and beta-blockade, respec-
tively) for at least four years. Patients were followed up until
at least 1,040 had experienced a first primary event, which
could be myocardial infarction (MI), stroke, or CV death.
In this 945-center trial from northern Europe, Britain, and
the U.S., the primary hypothesis was that losartan would be
more effective than atenolol in reducing CV morbidity and
mortality. Dosages were titrated to target pressures of
140 mm Hg systolic and 90 mm Hg diastolic: losartan
to 100 mg/day and atenolol to 100 mg/day, with hydro-
chlorothiazide 12.5 to 25 mg/day with or without other
therapies, excluding any of the randomized therapies and
ACE inhibition. Results. The systolic target was reached by
49.5% of patients in the losartan group (n  4,805) and
46.2% of patients in the atenolol group (n  4,588);
diastolic target was reached by 87.6% and 89.4%, respec-
tively. Over a mean follow-up of 4.8 years, the reductions in
adjusted and unadjusted risk for a first primary event for
patients who received losartan as compared with those who
received atenolol were 13.0% (p  0.021) and 14.6% (p 
0.009), respectively. Significantly more patients in the
atenolol group discontinued treatment due to adverse effects
(p  0.0001), which included bradycardia, cold body
extremities, hypotension, and sexual dysfunction. Mean
regression in LVH was significantly greater in the losartan
group than in the atenolol group. In a subgroup of 1,195
patients with diabetes according to WHO criteria, the
reductions in adjusted and unadjusted risk for a first primary
event for patients who received losartan as compared with
those who received atenolol were 24.5% (p  0.031) and
26.7% (p  0.017), respectively. Conclusions. When com-
pared with atenolol-based therapy, losartan-based therapy
in this group was associated with significant clinical benefits,
including reductions in CV morbidity and mortality, stroke,
new-onset diabetes, and improved LVH regression, given
similar degrees of BP reduction. Among diabetics, losartan
provided more pronounced protection against the primary
composite end point and total mortality, and losartan was
significantly better tolerated. Based on NHANES III sta-
tistics, the use of losartan instead of atenolol for 4.8 years by
patients meeting LIFE trial selection criteria would result in
70,000 fewer CV morbidity and mortality end points and
54,000 fewer cases of new-onset diabetes.
COMMENTARY
Beginning with the original Veterans Administration stud-
ies, for the last three decades we have been treated with a
series of placebo-controlled trials demonstrating that the
risk of death and other serious cardiovascular events can be
reduced by administering BP-lowering medications to in-
dividuals with hypertension. With the availability of several
distinct mechanistic classes of antihypertensive agents, there
has been a wide speculation regarding possible differential
influences of these therapies on clinical event rates beyond
those achieved by lowering BP. The LIFE study is one of
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several modern attempts to compare the relative efficacy of
different antihypertensive agents by using clinical end points
rather than surrogates. Higher-risk hypertensive patients
with electrocardiographic LVH were targeted. The patients
were randomized to initial antihypertensive control based
primarily on either the angiotensin-receptor blocker, losar-
tan, or the beta-blocker, atenolol, with hydrochlorothiazide
and then other antihypertensive agents added as needed to
achieve BP control. With 9,193 patients, more than four
years of follow-up, and over 1,000 events, the trial was
robust. Despite similar BP control, randomization to losar-
tan was associated with a lower risk for the composite end
point—CV death, stroke, and MI. Of these components,
the most preferentially altered by losartan therapy was the
risk of stroke. Other prespecified end points, such as
hospitalization for angina, heart failure, or revascularization
procedures were not differentially altered by two modes of
antihypertensive therapy. Of interest, losartan treated pa-
tients were less likely to be diagnosed with new onset
diabetes than atenolol treated patients.
The LIFE study is a major advance and ushers in a new
era of head-to-head antihypertensive trials, where the ques-
tions are whether an agent offers additional advantages
beyond the lowering of BP. Losartan was found to pro-
vide such a benefit. Other major drug comparison trials
(ALLHAT— chlorthalidone, lisinopril, amlodipine,
calcium-channel- blocker and VALUE—valsartan, amlo-
dipine) are well under way. As we advance with these
important fine-tuning studies comparing antihypertensive
agents, we must not lose sight of the fundamental impor-
tance of BP control and the disturbingly large segment of
our hypertensive population that currently remains undiag-
nosed or undertreated.
MARC A. PFEFFER, MD, PHD, FACC
DANAMI-2: The Danish Multicenter Randomized Trial of
Thrombolytic Therapy Versus Acute Coronary Angioplasty in
Acute Myocardial Infarction
HENNING RUD ANDERSEN, MD
SKEJBY UNIVERSITY HOSPITAL IN AARHUS,
AARHUS, DENMARK
Background. Emerging data from randomized trials sug-
gest a superior role for primary percutaneous coronary
intervention (PCI) when compared with fibrinolytic therapy
for patients presenting to centers that offer primary PCI.
But it remains unknown whether primary PCI is also
superior for patients who must be transferred to a PCI
center. Methods. The prospective, randomized DANAMI-2
trial encompassed 24 referral hospitals and five independent
angioplasty centers. The longest transport distance from
referral hospitals was 150 km (95 miles). A total of 1,572
patients (including 1,129 presenting to referral centers) were
randomized to treatment with front-loaded tPA (alteplase,
up to 100 mg, given at the presenting center without
transport) (n  782) or early transfer for primary PCI with
stenting (n  790). The primary end point was a composite
of mortality/reinfarction/disabling stroke at 30 days. The
inclusion criteria were symptoms for no longer than 12 h,
ST-elevation 4 mm, and ability to complete transfer to a
PCI center within 3 h of randomization. Cardiogenic shock
and malignant arrhythmias were exclusion criteria. Results.
The trial was stopped prematurely on October 1, 2001,
according to a safety and ethical committee recommenda-
tion. The primary end point had been reached by 13.7% of
patients who had received fibrinolytic therapy and 8.0% of
those who had received primary PCI (p  0.0003).
Whereas component rates of death and disabling stroke
were each nonsignificantly different between the two
groups, the reinfarction rate was significantly higher in the
fibrinolytic-therapy group: 6.3% versus 1.6% (p  0.0001).
Among the 1,129 patients randomized at referral hospitals,
the primary end point rates were 14.2% for the fibrinolytic-
therapy group and 8.5% for the primary-PCI group (p 
0.002). These rates for the 443 patients randomized at the
PCI centers (and who were, therefore, not transported) were
12.3% and 6.7%, respectively (p  0.048). Few adverse
events developed during any transport of PCI candidates;
atrial fibrillation occurred in 2.5% of such patients, ventric-
ular tachycardia in 0.2%, ventricular fibrillation in 1.4%, and
second- to third-degree atrioventricular block in 2.3%.
Conclusions. The DANAMI-2 trial showed a relative risk
reduction exceeding 40% for primary PCI versus front-
loaded tPA over 30 days. The trial, therefore, confirms
previous trials indicating that primary PCI is superior to
fibrinolytic therapy whether or not the PCI-treated patient
required transport to a PCI center, as long as transfer time
does not exceed 3 h. Transfer of patients with acute
myocardial infarction (MI) to PCI centers is safe.
COMMENTARY
The DANAMI-2 trial provides support for an early invasive
strategy for acute ST-elevation MI even if transfer to an
interventional center is required, as long as that transporta-
tion can occur in 3 h. Using a well-planned cooperative
national program involving 62% of Danish hospitals, the
investigators tested the hypothesis that immediate transfer
to an invasive hospital would produce equivalent or better
30-day composite outcomes of mortality, reinfarction, and
disabling stroke compared with local administration of
front-loaded TPA. Using this strategy, the investigators
demonstrated a 40% reduction in events for the patients
who underwent primary PCI. Time to mechanical reperfu-
sion was optimized for the transfer patients by preparing the
cath lab in the interventional hospitals during transfer. In
fact, the total time from presentation to balloon inflation
was only slightly longer for the transfer patients than for
patients who initially presented to the invasive hospital.
Importantly, transfer was associated with small numbers of
manageable complications.
Several comments should be noted. First, the relative use
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of adjunctive revascularization was remarkably low, partic-
ularly when compared with the U.S. (16% of patients had
unscheduled intervention or bypass surgery within 30 days),
for the transfer hospitals. Could a strategy of lytics with or
without adjunctive IIB to IIIA antagonists or low-
molecular-weight heparin coupled with semi-urgent trans-
fer for possible coronary intervention have provided equiv-
alent results? This question seems relevant because much of
the benefit of early transfer with coronary intervention was
not based on mortality or stroke reduction but on a
reduction in reinfarction, a benefit that may have been
provided equally well by intervention performed within 24 h
of the MI in thrombolytic patients without the need and
risk (albeit small) of urgent transfer. Such a strategy may
even reduce resource utilization and ultimate cost.
In summary, DANAMI-2 broadens the role of PCI in
ST-elevation MI to include patients who initially present to
a hospital at which PCI facilities are not available. Even
accounting for the time required to transfer the patient to a
PCI-capable hospital, patient outcomes were improved
compared with lytic therapy, with an acceptable risk of
in-transfer complications.
GEORGE W. VETROVEC, MD, FACC
A Randomized Trial of Fluvastatin After Successful
Percutaneous Intervention in Patients With Coronary Heart
Disease: The Lescol Intervention Prevention Study (LIPS)
PATRICK W. SERRUYS, MD, PHD, FACC
THORAXCENTER, ERASMUS UNIVERSITY HOSPITAL,
ROTTERDAM, THE NETHERLANDS
Background. Statins are now well established as therapy for
primary and secondary prevention of fatal and nonfatal
coronary events. Methods. In the LIPS trial, 1,677 patients
were randomized in a double-blind fashion to receive either
fluvastatin (40 mg bid) or placebo after a successful first
percutaneous coronary intervention (PCI) and were fol-
lowed up for three to four years. The primary end point was
survival free of major adverse cardiac events (MACE),
which encompassed cardiac death, nonfatal myocardial in-
farction (MI), surgical bypass, or repeat PCI. Secondary end
points included all-cause death, cardiac death, noncardiac
death, death or nonfatal MI, cardiac death or nonfatal MI,
lipid effects, and safety and tolerability. Patients were
required not to have been on lipid-lowering therapy for the
six weeks prior to randomization and to have a total
cholesterol 135 to 270 mg/dl and triglycerides 400 mg/dl.
A total of 1,141 lesions were treated by PCI in the
fluvastatin group (mean 1.35 per patient), and 1,083 lesions
were treated in the placebo group (mean 1.3 per patient).
Stents were used in more than half of the patients in both
groups. Results. The fluvastatin group showed a signifi-
cantly greater rate of MACE-free survival over four years
than the placebo group, with a risk reduction of 22% (p 
0.0127). The corresponding rates excluding re-PCI in the
first six months from the primary end point showed a risk
reduction of 34% with fluvastatin (p  0.0002). The
composite MACE rates over four years were 21.4% and
26.7% for the fluvastatin and placebo groups, respectively
(p0.006); however, differences in none of the component
end points individually reached significance. The risk ratios
significantly favored fluvastatin for the subgroups of patients
with multivessel disease and those with diabetes. The
MACE rates also were significantly lower for fluvastatin-
treated patients in these two subgroups (p  0.008 in
multivessel disease and p  0.022 in diabetes). Conclu-
sions. The LIPS trial supports the use of early lipid-
lowering therapy with fluvastatin after PCI in patients
initially having cholesterol levels in the normal range.
COMMENTARY
This large multicenter trial substantiates what cardiologists
have known, namely, that statins work not only for primary
prevention but also for secondary prevention of coronary
artery disease. The importance of this trial, which random-
ized patients with “normal cholesterol” who had undergone
a successful first PCI to placebo or fluvastatin, is that it
strongly emphasizes the critical nature of statin therapy in
this highest-risk group of patients.
The primary end point of this trial was survival free of
MACE, which included cardiac death, nonfatal MI, coronary
bypass graft surgery, or repeat PCI. The composite end point
was significantly reduced from 26.7% to 21.4% (p  0.006)
with fluvastatin. If repeat PCI is excluded from the primary
end point, there is an even more dramatic 34% reduction with
fluvastatin (p 0.0002). When the authors looked at high-risk
subsets of patients—for example, those with multivessel disease
and those with diabetes—MACE rates were significantly
lower in the patients treated with fluvastatin.
There are some issues that need to be addressed. This was
an intention-to-treat trial. Although the drug was generally
well tolerated, some of the fluvastatin-assigned patients
were no longer taking the drug at the end of four years.
Secondly, some of the patients who were originally random-
ized to placebo were subsequently treated with a statin.
These two findings could have resulted in narrowing of the
differences between the two groups. If analysis had been
performed according to treatment received, we can only
presume that there would have been an even more dramatic
difference between the two groups.
The fundamental message of this study is the importance
of statin drugs in the postprocedural care of coronary
interventional patients. These drugs are as important as
aspirin and thienopyridines.
DAVID R. HOLMES, JR, MD, FACC
Omapatrilat Versus Enalapril Randomized Trial of Utility
in Reducing Events (OVERTURE)
MILTON PACKER, MD, FACC
COLUMBIA PRESBYTERIAN MEDICAL CENTER,
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Background. The vasoconstrictor and vasodilator neuro-
hormonal systems normally oppose each other to achieve
homeostasis. But chronic heart failure (HF) is characterized
by a marked increase in the influence of endogenous
vasoconstrictors and a marked decrease in the influence of
endogenous vasodilators. These effects are particularly great
in severe chronic HF and probably contribute to the
development and progression of chronic HF. Angiotensin-
converting enzyme (ACE) inhibitors are the established
treatment for chronic HF, but these drugs inhibit only one
part of the endothelium-based peptide system that controls
vascular tone. Vasopeptidase inhibitors, which inhibit not
only ACE but also the co-localized enzyme neutral endo-
peptidase (NEP), modulate this peptide system more ex-
tensively. Combined inhibition of both enzymes not only
reduces the adverse influence of endogenous vasoconstric-
tors (due to ACE inhibition) but also potentiates the
favorable effect of endogenous vasodilators (due to NEP
inhibition). In experimental chronic HF models, combined
inhibition of both enzymes by a vasopeptidase inhibitor has
been shown to prolong life to a greater extent than ACE
inhibition alone. However, the possibility that vasopepti-
dase inhibitors might be superior to ACE inhibitors in
reducing mortality had not been previously explored in
patients with chronic HF. Methods. In the OVERTURE
study, 5,770 patients with moderate-to-severe chronic HF
were randomized to treatment with either the vasopeptidase
inhibitor omapatrilat (target dosage, 40 mg/day) or the
ACE inhibitor enalapril (target, 20 mg/day). Both agents
were given in addition to patients’ baseline chronic HF
medications for 0.8 to 2.3 years. Patients had New York
Heart Association (NYHA) class II to IV HF of any
etiology and a left ventricular ejection fraction 30% or lower.
The primary end point was all-cause mortality or HF
hospitalization. Secondary end points included cardiovascu-
lar (CV) death or hospitalization; CV death; and NYHA
class at eight months. The trial was designed to have 98%
power to detect a 15% difference in the primary end point
and 90% power to detect a 20% difference in all-cause
mortality. The design allowed for discrimination of nonin-
feriority of omapatrilat compared with enalapril and supe-
riority of omapatrilat compared with enalapril. The two
treatment groups were similar with respect to all baseline
characteristics. Of note, over 50% of the patients were
receiving a beta-blocker, and over 40% of the patients were
receiving spironolactone at the beginning of the trial.
Results. The primary end point rate for the 2,886 patients
who received omapatrilat was 31.7% and, for the 2,884
patients who received enalapril, was 33.7% (p  0.187).
This difference reflects a nonsignificant 6% lower risk in the
omapatrilat group. CV death or hospitalization was the only
secondary end point for which there was a significant
difference: 40.5% and 44.2%, respectively. Angioedema
developed in 0.8% and 0.5%, respectively. Conclusions.
Thus, OVERTURE did not demonstrate the superiority of
omapatrilat over enalapril. However, the upper bound of the
confidence interval was 1.09. Thus the trial fulfilled the
criteria for noninferiority. Therefore, omapatrilat was
shown to be an effective treatment for chronic HF and
therapeutically equivalent to enalapril.
COMMENTARY
Omapatrilat is a dual ACE inhibitor and NEP inhibitor
that has been widely studied in patients with hypertension
and HF. Preliminary data have suggested that the drug
might be more beneficial than ACE inhibitors alone.
Omapatrilat is associated with improved renal blood flow,
natriuresis, and a modest diuresis. It offers the added
advantage of increasing counter-regulatory natriuretic pep-
tide activity. In fact, omapatrilat blocks the degradation of a
number of peptides, including bradykinin. It has been
widely recognized that omapatrilat may be associated with a
higher incidence of angioedema than ACE inhibitors,
particularly in African Americans.
The OVERTURE study findings fail to support the
hypothesis that omapatrilat favorably alters the natural
history of patients with HF beyond that of conventional
therapy. The primary end point of all-cause mortality or HF
hospitalization was essentially similar both in the patients
treated with an ACE inhibitor and in those randomly
allocated to omapatrilat. As with any large randomized
controlled clinical trial, it is possible that the neutral
findings were at least in part due to an inappropriate dose.
However, this is speculation. Finally, in the era of modern
HF trials, it may be difficult to determine a unique or an
incremental beneficial effect of an investigational agent in
patients already receiving several effective drugs for the same
disorder. This may be particularly true if these agents share
common mechanisms of action.
It is perhaps becoming more difficult to demonstrate drug
superiority in the current era of polypharmacy in which so
many drugs are being used. We need to re-think how we
choose dose, select patients, and adjust concomitant medi-
cation in large clinical HF trials. Simply stacking numerous
neurohormonal blockers on top of each other may no longer
be an effective strategy to demonstrate efficacy. Finding
ways to select those patients who are the most likely to
respond to a specific treatment may be worth the effort.
GARY S. FRANCIS, MD, FACC
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